Brooke Daniel - Concepedia

Author

Brooke Daniel

Tennessee Oncology

Also Known As

Brooke Daniel, Brooke Daniel, MD, Brooke R. Daniel, Nuhad Ibrahim

Publications

1.2K

Citations

H-Index

Concepts

All Affiliations

Tennessee Oncology Florida Cancer Specialists & Research Institute Sarah Cannon Oncology Hematology Care University of North Carolina at Chapel Hill

About

Brooke Daniel is an author at Tennessee Oncology specializing in breast cancer, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	1K
2	Pharmacology	4	4	132
3	Health Sciences	2	2	914
4	Immunology	2	2	85
5	Pathology	2	2	879

Brooke Daniel

Publications

1.1K

Citations

H-Index

Page 1

	Year	Citations
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study Sandra M. Swain, David Miles, Sung‐Bae Kim, The Lancet Oncology End-of-study ResultsBreast OncologyMedicineClinical TrialsPathology	2020	854
Abstract PD13-07: Subgroup analysis of patients with brain metastases from the phase 3 ASCENT study of sacituzumab govitecan versus chemotherapy in metastatic triple-negative breast cancer Véronique Dièras, Robert Weaver, Sara M. Tolaney, Cancer Research Breast OncologyImmunologyImmunotherapeuticsHigh-grade GliomasNeuro-oncology	2021	60
Panitumumab, Gemcitabine, and Carboplatin as Treatment for Women With Metastatic Triple-Negative Breast Cancer: A Sarah Cannon Research Institute Phase II Trial Denise A. Yardley, Patrick J. Ward, Brooke Daniel, Clinical Breast Cancer Breast OncologyMedicineBreast CancerCancer TreatmentOncology	2016	44
Ramucirumab With Eribulin Versus Eribulin in Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracycline and Taxane Therapy: A Multicenter, Randomized, Phase II Study Denise A. Yardley, James A. Reeves, Elizabeth Claire Dees, Clinical Breast Cancer	2016	32
TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early-stage triple-negative breast cancer Denise A. Yardley, Edward Arrowsmith, Brooke Daniel, Breast Cancer Research and Treatment Breast OncologyMedicinePharmacologyBreast CancerAnti-cancer Agent	2017	27
Saci-IO TNBC: Randomized phase II trial of sacituzumab govitecan (SG) +/- pembrolizumab in PD-L1– metastatic triple-negative breast cancer (mTNBC). Ana C. Garrido-Castro, Tanya E. Keenan, Tianyu Li, Journal of Clinical Oncology Breast OncologyImmunologyPathologyImmunotherapeuticsImmunotherapy	2021	25
A Phase II Trial of Dose-Dense Neoadjuvant Gemcitabine, Epirubicin, and Albumin-Bound Paclitaxel With Pegfilgrastim in the Treatment of Patients With Locally Advanced Breast Cancer Denise A. Yardley, John D. Zubkus, Brooke Daniel, Clinical Breast Cancer Breast OncologyOncologyPhase Ii TrialMedicineAlbumin-bound Paclitaxel	2010	20
Addition of bevacizumab to three docetaxel regimens as adjuvant therapy for early stage breast cancer Denise A. Yardley, Lowell L. Hart, David Waterhouse, Breast Cancer Research and Treatment	2013	10

Page 1